Intercept Pharmaceuticals (Nasdaq:ICPT) - Hisse Senedi Fiyatı, Haberler ve Analizler

ICPT Stoklara Genel Bakış

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada.

Şirket hakkında

ICPT temel anali̇z
Kar Tanesi Skoru
Değerleme	5/6
Gelecekteki Büyüme	4/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 53.1% daha düşük bir oranda işlem görüyor

Kazançların yılda 42.37% oranında artması öngörülüyor

Kazançlar son 5 yılda yılda 22.4% oranında arttı

Rakiplerine ve sektöre kıyasla iyi değerde işlem görüyor

Risk Analizi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Intercept Pharmaceuticals, Inc. Rakipler

Zenas BioPharma

NasdaqGS:ZBIO

US$855.2m

Ironwood Pharmaceuticals

NasdaqGS:IRWD

US$667.7m

Avid Bioservices

NasdaqCM:CDMO

US$655.2m

Prothena

NasdaqGS:PRTA

US$895.4m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Intercept Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$19.00
52 Haftanın En Yüksek Seviyesi	US$21.86
52 Haftanın En Düşük Seviyesi	US$8.82
Beta	0.88
11 Aylık Değişim	1.99%
3 Aylık Değişim	81.30%
1 Yıllık Değişim	19.12%
33 Yıllık Değişim	-50.68%
5 Yıllık Değişim	-81.17%
Halka arzdan bu yana değişim	-2.06%

Son Haberler & Güncellemeler

Recent updates

Revenues Working Against Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price Following 25% Dive

Jun 08

Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?

Apr 11

Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?

Dec 20

Intercept touts Ocaliva benefit in transplant-free survival in liver disease type

Sep 20

Need To Know: Analysts Are Much More Bullish On Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

May 10

Intercept: Opportunity To Buy On Potential NDA Resubmission Of Ocaliva For NASH

Mar 05

Intercept names Andrew Saik as chief financial officer

Jun 07

Intercept Pharmaceuticals slides as FDA restricts Ocaliva use

May 26

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Are Analysts Optimistic?

May 11

Hissedar Getirileri

	ICPT	US Biotechs	US Pazar
7D	0.1%	-1.4%	-1.9%
1Y	19.1%	20.2%	30.4%

Getiri vs. Endüstri: ICPT geçen yıl % 20.2 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: ICPT geçen yıl % 30.4 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is ICPT's price volatile compared to industry and market?
ICPT volatility
ICPT Average Weekly Movement	22.8%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

İstikrarlı Hisse Senedi Fiyatı: ICPT hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: ICPT 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 15% dan 23% a yükseldi.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2002	341	Jerry Durso	www.interceptpharma.com

Intercept Pharmaceuticals, Inc. Temel Bilgiler Özeti

Intercept Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ICPT temel i̇stati̇sti̇kler
Piyasa değeri	US$794.69m
Kazançlar(TTM)	-US$57.47m
Gelir(TTM)	US$317.68m

2.5x

P/S Oranı

-13.8x

F/K Oranı

ICPT aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ICPT gelir tablosu (TTM)
Gelir	US$317.68m
Gelir Maliyeti	US$632.00k
Brüt Kâr	US$317.05m
Diğer Giderler	US$374.52m
Kazançlar	-US$57.47m

Son Raporlanan Kazançlar

Sep 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.37
Brüt Marj	99.80%
Net Kâr Marjı	-18.09%
Borç/Özkaynak Oranı	311.6%

ICPT uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

ICPT Stoklara Genel Bakış

Ödüller

Risk Analizi

Intercept Pharmaceuticals, Inc. Rakipler

NasdaqGS:ZBIO

US$855.2m

NasdaqGS:IRWD

US$667.7m

NasdaqCM:CDMO

US$655.2m

NasdaqGS:PRTA

US$895.4m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Intercept Pharmaceuticals, Inc. Provides Regulatory Update Regarding sNDA for OCALIVA

Intercept Announces Statement on FDA Advisory Committee Meeting

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024

Intercept Pharmaceuticals, Inc. Files Form 15

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Recent updates

Intercept Pharmaceuticals, Inc. Provides Regulatory Update Regarding sNDA for OCALIVA

Intercept Announces Statement on FDA Advisory Committee Meeting

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024

Intercept Pharmaceuticals, Inc. Files Form 15

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals' Common Stock Ceased to be Traded on the NASDAQ Stock Market

Alfasigma S.p.A. completed the acquisition of Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT).

Third quarter 2023 earnings: EPS exceeds analyst expectations

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

Alfasigma S.p.A. entered into a definitive merger agreement to acquire Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT) for approximately $840 million.

Now 20% undervalued after recent price drop

Now 22% undervalued after recent price drop

Intercept Pharmaceuticals Provides Net Sales Guidance for the Full Year of 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Intercept Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Price target decreased by 24% to US$15.08

Intercept Pharmaceuticals, Inc. Presents New Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage

Intercept Pharmaceuticals, Inc. Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023

Revenues Working Against Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price Following 25% Dive

Price target decreased by 14% to US$21.00

Forecast breakeven date moved forward to 2024

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 11%

Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?

Price target increased by 9.9% to US$24.00

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 8.2% to US$20.85

U.S. Food and Drug Administration Accepts Intercept Pharmaceuticals, Inc.'s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to Nash

Consensus forecasts updated

Forecast breakeven date pushed back to 2025

Intercept Pharmaceuticals, Inc. Resubmits New Drug Application to U.S. Fda for Obeticholic Acid in Patients with Liver Fibrosis Due to NASH

Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?

Consensus forecasts updated

Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Intercept Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid in Compensated Cirrhosis Due to Nash Did Not Meet Its Primary Endpoint

Price target decreased to US$24.00

Intercept Pharmaceuticals, Inc. Announces Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology

Intercept touts Ocaliva benefit in transplant-free survival in liver disease type

Intercept cuts debt further with deal to exchange convertible notes

Intercept reduces debt with repurchases of $327.9M convertible notes

Intercept Pharmaceuticals: Too Risky To Buy At This Stage

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Intercept Pharma Q2 2022 Earnings Preview

Intercept Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Intercept Pharmaceuticals, Inc. Announces Resignation of Bryan Ball as Chief Quality Officer and Senior Vice President of Operations, Effective August 12, 2022

Consensus forecasts updated

Forecast breakeven date moved forward to 2022

Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)

Intercept to resubmit for FDA approval of NASH candidate after new analysis

Intercept Pharmaceuticals, Inc. Provides Update on Nash Regulatory Timeline

Intercept Pharmaceuticals, Inc. Announces Resignation of Gail Cawkwell as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance

Intercept: Increase Of Ocaliva Sales And A Few Catalysts

Consensus estimates of losses per share improve by 93%